What Pyxis Oncology Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 1 |
| Total trades | 0 | 3 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 144,461 |
| Disposed | 0 | 35,000 |
| Net activity | +0 | +109,461 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Dupont Jakob | Director | Jun 30 | Disclosed 10b5-1 sale · S | −35,000 | $3.06 | −$107K | 38,741 |
| Dupont Jakob | Director | Jun 30 | Exercise / conversion · M | +35,000 | $1.60 | +$56K | 73,741 |
| Wadhane Jitendra | Prin Fin & Acct Officer | Mar 24 | Grant / award · A | +109,461 | — | — | 512,882 |
| Humphrey Rachel | Director | Apr 21 | Disclosed 10b5-1 sale · S | −13,896 | $1.03 | −$14.4K | 81,309 |
| Humphrey Rachel | Director | Apr 17 | Disclosed 10b5-1 sale · S | −200 | $0.97 | −$194 | 95,205 |
| Humphrey Rachel | Director | Apr 14 | Disclosed 10b5-1 sale · S | −1,400 | $0.97 | −$1.36K | 95,405 |
| Yanchik Connealy Pamela | CFO & COO | Nov 26 | Open-market buy · P | +83,400 | $1.96 | +$163K | 1,199,143 |
| Yanchik Connealy Pamela | CFO & COO | Nov 26 | Open-market buy · P | +5,450 | $2.00 | +$10.9K | 1,115,743 |
| Palani Santhosh | Director | Jun 07 | Grant / award · A | +6,000 | — | — | 6,000 |
| Yanchik Connealy Pamela | CFO & COO | Mar 26 | Grant / award · A | +328,710 | — | — | 1,110,293 |
| Dupont Jakob | Director | Mar 26 | Grant / award · A | +38,741 | — | — | 38,741 |
| Wadhane Jitendra | SVP, Chief Accounting Officer | Mar 26 | Grant / award · A | +131,484 | — | — | 398,421 |
| Cline Darren S | Director | Mar 26 | Grant / award · A | +35,219 | — | — | 251,405 |
| Humphrey Rachel | Director | Mar 26 | Grant / award · A | +38,741 | — | — | 96,805 |
| Lewis-Hall Freda C | Director | Mar 26 | Grant / award · A | +35,219 | — | — | 241,405 |
| Flavin John L | Director | Mar 26 | Grant / award · A | +35,219 | — | — | 413,015 |
| Yanchik Connealy Pamela | CFO and COO | Nov 29 | Withheld — tax / exercise cost · F | −36,949 | $1.40 | −$51.7K | 781,583 |
| Wadhane Jitendra | Chief Accounting Officer | Nov 15 | Grant / award · A | +40,000 | — | — | 266,937 |
| Yanchik Connealy Pamela | CFO and COO | Sep 28 | Open-market buy · P | +8,000 | $1.87 | +$15K | 818,532 |
| Yanchik Connealy Pamela | CFO and COO | Sep 27 | Open-market buy · P | +6,426 | $1.85 | +$11.9K | 810,532 |
Loading...
